Skip to content

One Dose Versus Three Weekly Doses of Benzathine Penicillin G for Patients With Early Syphilis

Doctor of Medicine

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02857959
Enrollment
150
Registered
2016-08-05
Start date
2016-08-31
Completion date
2020-08-31
Last updated
2018-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Syphilis

Brief summary

The purpose of this study is to observe the serological response to 1 or 3 weekly doses of benzathine penicillin G in patients with early syphilis.

Interventions

Sponsors

Jun Li
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Persons with confirmed early symptomatic syphilis (primary or secondary) or high-titer latent syphilis 2. A rapid plasma reagin (RPR) test was positive, with a titer were 1:4 or higher. In addition, Treponema pallidum particle agglutination assay and/or fluorescent treponemal antibody absorption test were reactive.

Exclusion criteria

1.Patients who were pregnancy, known allergy to penicillin, use of antibiotics active against syphilis during the preceding six months for symptomatic cases or during the preceding two years for asymptomatic cases, and concurrent illnesses requiring treatment with antibiotics effective against syphilis. 2. if RPR titers were found to be 1:4 or less or the T. pallidum particle agglutination test was nonreactive, participants were retrospectively excluded from the trial unless primary syphilis was confirmed by the finding of T. pallidum in ulcer exudates on direct immunofluorescence \-

Design outcomes

Primary

MeasureTime frame
Rapid plasma reagin titersup to 9 months after treatment

Countries

China

Contacts

Primary ContactJun Li, M.D.
lijun35@hotmail.com86-010-69151504

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026